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Volume expansionThe bufodienolides are cardiac glycosides which have the ability to inhibit the enzyme, Na+/K+ ATPase
(sodium potassium adenosine triphosphatase). They are cardiac inotropes, cause vasoconstriction (and,
potentially, hypertension) and are natriuretic. Evidence has accrued over time which supports the view that
they are mechanistically involved in volume expansion-mediated hypertension. In this communication, the
authors summarize data which support the view that the bufodienolides and, in particular, marinobufagenin
(MBG) are involved in the pathogenesis of preeclampsia. In a rat model of the syndrome, MBG causes
hypertension, proteinuria, intrauterine growth restriction and increased weight gain. All of these phenotypic
characteristics are prevented by an antagonist to MBG, resibufogenin (RBG). The “preeclamptic” animals also
develop a vascular leak syndrome, resulting in hemoconcentration. Abnormalities in the MAPK (mitogen-
activated protein kinase) system play a role in the mechanism by which MBG produces the abnormalities in
the pregnant rat. Studies to discover the relevance of these ﬁndings to human preeclampsia are currently
underway in several laboratories and clinics.bufogenin; AT1-AA, agonistic
ctivated protein kinase; IL-6,
S, renin–angiotensin system;
phatase
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1.1. The bufodienolides
The bufodienolides are a group of steroid compounds that are
classiﬁed as cardiac glycosides [1–3]. They differ from the cardeno-
lides, separate but similar members of the cardioactive steroid group,
in chemical structure (Fig. 1) and in their cellular mechanisms of action
[1–3]. The bufodienolides consist of steroid nuclei with a 6-member
lactone ring, while the cardenolides possess a 5-membered lactone ring
[3]. The presence of some of the bufodienolides in the ancient Chinese
medicines, Chan Su, Liu-Shen, Niu-Huang-Xiao-Yen and Ya-Tong-Ya [4]
and their analytical cross-reaction with the major cardenolide, digoxin,
has led to the interference of the bufodienolides with assays employed
to determine digoxin toxicity [5,6]. The bufodienolides are active
constituents in Chan Su found in the skin and venomof the toad [7], and
are also present in plants [8–10]. The cardiac glycosides are so named
becauseof their ability toact as cardiac inotropes.However, they are also
capable of causing vasoconstriction, which may lead to hypertension,and, by inhibiting the ubiquitous enzyme, Na/K ATPase, of causing
natriuresis [1–3].
The most widely studied of the bufodienolides is marinobufagenin
(MBG). This substance has been implicated in a variety of physiolog-
ical and pathophysiological circumstances. The latter include volume
expansion-mediated hypertension [11–15], volume expansion and
volume overload [16–19], preeclampsia [12,20–24], endothelial cell
function [25,26] and cellular growth and differentiation [3,27,28].
Resibufogenin (RBG) is a bufodienolide which differs from MBG
only in the absence of a hydroxyl group in the β-5 position (Fig. 1).
Recent studies have demonstrated that RBG has the capability to act as
an antagonist of MBG in a number of experimental circumstances.
This review will focus primarily on these two compounds, discussing
the role of MBG in the pathophysiology of volume expansion-
mediated hypertension (including “salt-sensitive” hypertension)
and in the potential therapeutic role of its antagonist, RBG.
2. Background information
2.1. Volume expansion
In the late 1950s and early in the 1960s, a topic of animated
discussion in nephrology was the question as to what the physiologic
mechanisms are that result in the unfailing natriuresis that follows the
imposition of volume expansion [29]. It was clear that at least two
factors are involved: 1) an increase in glomerular ﬁltration rate (GFR)
with an attendant increase in the ﬁltered load of sodium and, 2) the
reduction in the circulating levels of mineralocorticoids (especially
Fig. 1. Chemical structures of the bufodienolides and the cardenolides. These two groups of agents each have a steroid nucleus. However, the bufodienolides have a six-member,
while the cardenolides have a ﬁve-member lactone ring. The sole difference between the chemical structures of marinobufagenin and resibufogenin is the absence of a hydroxyl
group in the β-5 position of resibufogenin.
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if one corrected for these factors, preventing them from changing
during acute volume expansion, natriuresis nevertheless occurred
[30–32]. There arose, therefore, the concept that some other factor,
so-called “third factor”must be involved [32]. Over time, the postulate
that a secreted circulating hormonal factor was released as a
consequence of volume expansion became the subject of intense
investigation [33–37]. Accordingly, a search for such a humoral factor
began. It became evident that alterations in physical factors at the
renal tubular level played an important role [38–40], but could not
completely explain the resultant natriuresis. In a series of ingenious
experiments, De Wardener and his colleagues performed studies in
which blood was cross-circulated from one dog to another, one ofwhich had received intravenous saline [30,31]. They noted that
despite careful adjustment of GFR and the ﬁltered load of sodium in
the recipient dog so that they matched or were lower than pre-
expansion levels, and the provision of supraphysiologic amounts
of mineralocorticoid, natriuresis nevertheless eventuated [30,31].
Subsequently, Lichardus and Pearce [35] as well as Johnston and Davis
[41] conﬁrmed these observations.
Employing toad bladder transport of sodium, Gruber, et al. showed
that dialysates of plasma from volume expanded dogs interfered with
the short-circuit current representing sodium transport, whereas
plasma samples from control dogs had no such effect [42]. They
subsequently identiﬁed a low molecular weight molecule which
inhibited renal Na/K ATPase [43].This substance competed with
Fig. 2. Increments of blood and plasma volumes throughout pregnancy.
Reproduced from Scott, DE, Anemia in pregnancy, In: Wynn R.M., ed., Obstet. Gynecol.
Ann., Appleton, Century, Crofts New York 1972;1:219–244, with permission of the
editors.
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an endogenous digitalis-like compound [43].
3. Volume expansion-mediated hypertension
3.1. Endogenous digoxin-like factor (EDLF)
Blaustein, Hamlyn and their colleagues proposed that this so-
called “natriuretic factor” interferedwith sodium potassium exchange
in vascular smoothmuscle cells, likely due to its ability to inhibit Na/K
ATPase [44]. In consequence, these cells became depolarized, resulting
in an increase in intracellular sodium concentration. In turn,
intracellular calcium was increased by exchange for sodium via the
sodium/calcium exchanger. Consequently, the added calcium ion
would become sequestered, increasing the intracellular calcium pool,
resulting in vasoconstriction [45,46]. Included in the possible
endogenous circulating factors, besides digoxin and, possibly, ouabain
(the major cardenolide inhibitors of Na/K ATPase) is the bufodieno-
lide, MBG. It has been demonstrated that Na/K ATPase inhibition
and volume expansion are commonly observed elements in animals
[11–13,15,17,18,20,47,48] and humans [19,21] in which levels of
bufodienolides in blood and/or urine are elevated. In addition toMBG,
these include telocinobufagin (Fig. 1) [49]. Furthermore, antibodies to
MBG injected into volume expanded, hypertensive rats result in the
lowering of blood pressure [20]. These agents were considered not
only to directly exert vasoconstrictor effects as a result of enhanced
calcium levels in vascular smooth muscle related to Na/K ATPase
inhibition, but also to have direct vasoconstrictive activity unrelated
to the activity of the enzyme [45,50]. Evidence for the involvement of
the cardenolides, ouabain and digoxin, as the “natriuretic factor”
causing hypertension has been conﬂicting. For details of these data,
the reader is referred to a recent review [51].
3.2. Endogenous bufodienolides
As mentioned previously, the bufodienolides differ structurally
from the cardenolides [1–3] (Fig. 1). In addition, they have differing
effects on the isoforms of Na/K ATPase. Thus, the bufodienolides
preferentially bind to the α1 isoforms, whereas the cardenolides have
a predilection for the α2 and α3 forms [3]. Bufodienolides have been
identiﬁed in the skin and the venom of amphibia [51,52]. MBG has
also been isolated from the plasma and urine of mammalian species,
including rats, dogs, and, more recently, humans [11,15,17–23,48].
The major stimulus for its secretion and elaboration appears to be
volume expansion. Therefore, the concept arose that forms of
hypertension related to volume expansion versus those due to
vasoconstriction might involve the bufodienolides from a pathoge-
netic standpoint [16,53,54]. As mentioned previously, study of plasma
and urine from expanded animals reveals that they most likely
contain a number of cardiac glycosides, which share the capacity to
inhibit Na/K ATPase.
The more recent recognition that both cardenolides and bufodie-
nolides are likely to play a role in the effects of these cardiotonic
steroids, led to better delineation as to which of these substances is
responsible for their biologic effects [1–3,51].
4. Preeclampsia
Preeclampsia is a syndrome of pregnancywhich occurs in 3–10% of
all gestations [55,56]. It is the second leading cause of maternal and
fetal morbidity andmortality in the United States and abroad.Women
who receive no prenatal care are reported to be more than seven
times as likely to die from complications of preeclampsia or eclampsia
as women who do receive any prenatal care [57]. From 1987 until
1982, 15% of the hospitalizations for complications of pregnancy were
reported to be for hypertension [58]. Preeclampsia consists in thedevelopment of hypertension and proteinuria after 20 weeks of
gestation. The disorder is often complicated by the occurrence of
intrauterine growth restriction (IUGR) and is associated with preterm
birth. Both of the latter conditions prejudice the survival and well-
being of the fetus [59]. The only current deﬁnitive therapy is delivery
of the fetus and placenta. The latter appears to be a major offending
organ in this disorder. There is, as yet, no completely reliable
biomarker for early diagnosis [60] and no effective pharmacological
therapy. Furthermore, preeclampsia is a syndrome and not a single
disease process, no doubt involving multiple etiologic factors
[55,56,61]. It therefore represents an example of substantial unmet
medical need.
Recent research efforts in preeclampsia have produced interesting
observations, which could represent novel approaches not only to its
diagnosis and therapy, but also, its prevention. These include data
suggestive of the importance of an imbalance between pro- and
antiangiogenic factors [62,63], agonistic autoantibodies to the AT 1
receptor [64] and the possibility that circulating inhibitors of Na/K
ATPase play important roles in human preeclampsia [21–23,53,65,66]
and in an animal model of the syndrome [20]. Pregnancy is nature's
own experiment in volume expansion. During gestation, women gain
an additional 40–50% of extracellular ﬂuid (ECF) volume [67, Fig. 2].
Given the data summarized above indicating that volume expansion is
a major stimulus for MBG secretion and elaboration, the authors and
their colleagues established a model of preeclampsia in the rat. The
animals were volume expanded by replacing their drinking water
with saline and injecting desoxycorticosterone acetate (DOCA) in a
depot form on a weekly basis [68]. The result was the development of
a syndrome with many of the phenotypic characteristics of human
preeclampsia [69]: hypertension, proteinuria, IUGR, excessive weight
gain and increased urinary excretion of MBG [14,20,68,70]. In
addition, the diameters of the decidual vessels dissected from the
uteri of the “preeclamptic” animals were narrower than those
obtained from normal pregnant animals [14, Fig. 3]. Interestingly,
their perfusion with a solution containing MBG caused a further
constriction of 36%, whereas the vessels from normal pregnant
animals did not respond to the bufodienolide [14]. These observations
indicate “sensitization” of the arterioles to MBG in this preeclamptic
model. Furthermore, the injection of antibodies to MBG resolved the
hypertension. In conﬁrmation of the involvement of MBG in the
preeclamptic syndrome, Federova, et al. have reported that an
antibody to MBG lowered elevated blood pressure in pregnant rats
rendered hypertensive by treatment with high salt diets [12,13].
Of special interest is the fact that several aspects of the
preeclamptic process can be reproduced by excessive volume
expansion and the involvement of MBG. Of crucial importance in
successful gestation is the process of “placentation” [71]. Shortly after
implantation, a group of specialized cells, the cytotrophoblasts (CTBs),
Fig. 3. Representative magniﬁed images of the uterine arterioles dissected from normal pregnant (NP) and “preeclamptic” (PDS) rats. The initial arteriolar diameters of the PDS rats
were signiﬁcantly narrower (93.6±3.5 µm) than those taken from the uteri of normal pregnant animals (110.6±6.1 µm; pb0.05). The arterioles from the PDS rats constricted by an
average of 36% when compared to pretreatment vessel diameter measurements. This vasoconstriction was not seen in the arterioles of the normal pregnant animals.
Reproduced (with permission of the editors) from: Am J Nephrol 2005;25:520–528.
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purpose is to remodel the vasculature of the uterus such that high
resistance, small bore vessels are transformed into large diameter, low
resistance channels [71–73]. Presumably, this process occurs for the
purpose of increasing blood ﬂow to the maternal–fetal unit to assure
proper delivery of basic nutrients and oxygen. Therefore, the effects of
MBG on CTB function were examined in CTB cells in tissue culture
[27,74]. It was determined that MBG-induced impairment of CTB
function occurs via activation of Jnk, p38 and Src, leading to increased
apoptosis and IL-6 secretion. The enhancement of the apoptotic
effects of MBG on CTB could be attenuated by p38 inhibition [28].
Because the degree to which expansion of the ECF volume exceeds
the increment in red cell mass, pregnant patients develop so-called
“physiologic anemia” [67]. However, preeclamptic patients have been
noted to have hematocrit values higher than those in normal pregnant
subjects. These observations led to the concept that preeclamptic
patients are hemoconcentrated. This aspect of human preeclampsia
was reproduced in the rat model.
Thus, normal nonpregnant females had mean hematocrit values of
0.44±0.01, while in normal, pregnant females, this value is 0.34±
0.02 and in “preeclamptic” rats, the mean was 0.38±0.02. All three of
these levels differed statistically from each other (pb0.05). Substan-
tial evidence has accrued that preeclampsia represents an endothelial
cell disorder [75,76]. Therefore, it has been proposed that, along with
other evidence, these ﬁndings suggest a “vascular leak syndrome”
with ﬂuid transferring from the intravascular to the interstitial space
[77,78, Fig. 4]. Furthermore, it has been proposed that endothelial cell
dysfunction and oxidative stress are regularly observed phenomena in
preeclampsia [76]. These matters were addressed in a DOCA-salt
rat model of volume expansion-mediated “essential” hypertension
[16] and in the rat model of preeclampsia described above [79] as well
as in in vitro studies [25]. In the former animals, the production of
superoxide anion was increased over control [16]. In the preeclamptic
model, mesenteric endothelial-dependent relaxation responses and
aortic nitric oxide (NO) production were signiﬁcantly decreased
despite increased aortic eNOS expression. Furthermore, the scaveng-
ing of reactive oxygen species or increased tetrahydrobiopterin levels
normalized the relaxation responses, aortic NO production and aortic
superoxides and peroxynitrile levels [80].
5. MBG and angiogenic factors
The authors endorse the concept that preeclampsia represents a
syndrome with multiple etiopathogenetic factors [53,54,60,81]. That
these factors may show some interrelationship in the pathogeneticprocess of this disorder also seems likely. In addition, the issue of the
sequence of the involvement of these factors in the events leading to
hypertension, proteinuria, IUGR, “vascular leak”, and perhaps neuro-
logical abnormalities [82], remains to be determined. In the evaluation
of the time sequence of these events, the authors have compared the
time course of the appearance of abnormalities in angiogenic factors
relative to the appearance of the increased secretion and elaboration
of MBG [14]. In preliminary studies performed in the expansionmodel
of preeclampsia [68] the timing of the increased excretion of MBG [14]
was compared to that of changes in pro- and antiangiogenic factors
[83]. Preliminary data reveal no changes in angiogenic factors at the
3–5 day gestational period in “preeclamptic” rats. At this time, MBG
excretion in the urine is already elevated [14, Fig. 5]. Reductions in
VEGF and increases in SFlt-1 began at the 7–10 day time-period
(Agunanne, et al, unpublished observations). Furthermore, RBG, given
early in pregnancy, prevented angiogenic imbalance as well as the
phenotypic characteristics of the preeclamptic syndrome in this rat
model [83].
6. Neurologic complications of preeclampsia
Given the vascular leak syndrome induced by MBG and its
presence in our “preeclamptic” animals [79], its role was investigated
in human brain monolayer endothelial cells [84]. Preliminary data
indicate that, as was the case in mesenteric postcapillary venules [79],
the addition of MBG to endothelial cell monolayers obtained from
human brain vasculature resulted in evidence of the induction of
hyperpermeability [84]. This breach of the blood/brain barrier has
been conﬁrmed in preliminary studies involving the injection of
Evan's blue dye in PDS rats (Bake, et. al, unpublished observations).
Given the elevation in MBG blood levels observed in human
preeclamptic patients [21–23], these data could implicate MBG in
the causation of neurologic symptoms and abnormalities in this
hypertensive syndrome of pregnancy as previously described
[82,85,86]. In experiments performed in pregnant rats, acute eleva-
tions of blood pressure resulted in autoregulatory breakthrough,
blood/brain barrier disruption and cerebral edema [87]. The latter
investigation also provided evidence in the acute hypertensive rat
model that pregnancy may prevent hypertensive remodeling of
cerebral arteries [88].
7. Conclusions and perspectives
It now seems well established that preeclampsia is not a single
disease process, but a syndrome with multiple etiologic factors
Fig. 4. a. Representative study demonstrating the effect of MBG on vascular leakage in a single rat mesentery postcapillary venule. Images shown were obtained prior to the injection
(0 min) and at 30 and 60 min after the bolus injection of 200 nMMBG. FITC-albumin extravasation into the extravascular space is virtually complete by 60 min after MBG injection.
b. Comparison of vascular leakage in mesenteric postcapillary venules in three groups of female rats: control = nonpregnant female animals (n=5); normal pregnant (NP) rats
(n=9); pregnant animals administered DOCA and saline (PDS) (n=9). NP rats showed leakage of dye at 80–90 min (pb0.05). PDS rats showed signiﬁcant leakage beginning at
20 min (pb0.05) when compared to control and NP rats. ⁎pb0.05 vs. control, †pb0.05 vs. NP, and ‡pb0.006 vs. control.
Reproduced (with permission of the editors) from Am J Nephrol 2009;30:26–33.
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possible to develop a single test to predict its forthcoming superven-
tion, but rather a panel of tests will be required. Excessive volume
expansion before the 8–10 week gestation period in sensitive
pregnant patients may serve as a stimulus for the elaboration of
excessive amounts of the bufodienolide, MBG, (and perhaps others).
This sequence of events could result in the development of a reliable
predictive test. Data are also available in the animal model, but not yet
in human subjects, indicating that MBG is elevated prior to both theFig. 5. Time sequence of the MBG urinary excretion pattern in control rats (C), normal
pregnant animals (NP) and pregnant animals treated with DOCA weekly injections and
whose drinking water had been replaced with saline, rendering them “preeclamptic”
(see text) (PDS rats). Time periods: t0=baseline, nonpregnant state; t1=3–5 days of
pregnancy; t2=7–10 days of pregnancy; t3=16–19 days of pregnancy. MBG excretion
was already statistically signiﬁcantly elevated at time t1 although the animals did not
become hypertensive and proteinuric until time t2.
Reproduced (with permission of the editors) from: Am J Nephrol, 2005;25:520–528.onset of angiogenic imbalance and the development of hypertension
and proteinuria. Of critical importance in these animal studies, is the
fact that the early administration of the antagonist of MBG, RBG,
prevents angiogenic imbalance as well as preventing the animal
“preeclamptic” syndrome. Studies are currently underway in which
sequential analyses of MBG and markers of pro- and antiangiogenic
factors are to be examined for their appearance in human subjects
with preeclampsia compared to those obtained in normal pregnant
patients. Studies are also planned to evaluate polymorphisms/
mutations in sodium transporters in these two patient populations
to determine if those patients with elevatedMBG levels are also found
to have abnormalities in sodium transporters.
What constitutes the continued stimulus for MBG secretion once
hemoconcentration has appeared, despite the fact that the patient
remains expanded with substantial ﬂuid having been extravasated
into the interstitial compartment and resulting in a reduction in
intravascular volume? We postulate that at this time in the gestation
process, MBG has exerted its baleful effects on CTB function.
Accordingly, normal vascular remodeling of the decidual vessels has
been prevented and hypoperfusion of the maternal–fetal unit has
occurred. The ischemic/hypoxic stimuli resulting from the restricted
blood ﬂow to these organs could cause the continued increase in MBG
levels [89,90]. It is clear from animal and in vitro experiments, that
MBG may be complicit in the “vascular leak” that typiﬁes the
preeclamptic syndrome. The challenge remains to demonstrate
these observations elicited in the animal model, in human subjects.
If the latter can be proven, the reward is potentially quite high: that is,
that RBG may serve as an important new preventative as well as
a therapeutic agent. Also of potential value and importance may
be interference in the pathogenetic pathway with inhibition, for
Fig. 6. Proposed three-phase model of the involvement of MBG in the pathogenesis of preeclampsia: Phase I (early-mid ﬁrst trimester): initially, excessive volume expansion occurs
in early pregnancy, related to difﬁculty in sodium disposal. The latter is postulated to be due to an inherited or acquired defect in sodium excretion. This causes elevated levels of
MBG. MBG exerts its effects by inhibiting Na+/K+-ATPase. It may also interact with other membrane receptors. Phase II (mid-late ﬁrst trimester): the elevated levels of MBG cause
cytotrophoblast dysfunction and, consequently, defective placentation. This results in impaired uterine vascular remodeling and hypoperfusion of the maternal–fetal unit. The
resultant hypoxia and ischemia, lead to continued elevation ofMBG levels and, additionally, to an imbalance in angiogenic factors. Early administration of RBG prevents this sequence
of events, including the development of angiogenic imbalance. Development of agonistic autoantibodies to the AT1 receptor may also initiate endothelial dysfunction. Additionally,
MBG causes increased vascular permeability resulting in leakage from the intravascular compartment and consequent hemoconcentration. The latter further compromises blood
ﬂow to the maternal–fetal unit. The cytotrophoblast dysfunction is mediated by alterations in the MAPK system which stimulates apoptosis causing disruption of endothelial cell
layers. Inhibition of the activity of p38 prevents the MBG-induced enhancement of apoptosis and IL-6 secretion. Phase III (mid-late second trimester): all of these abnormalities
culminate in the production of endothelial cell dysfunction and oxidative stress. These phenomena result in the induction of the syndrome of preeclampsia including hypertension,
proteinuria, IUGR, vascular leak and hemoconcentration. RBG administration early in pregnancy prevents the development of this syndrome and its phenotypic characteristics.
Abbreviations: MBG = marinobufagenin, RBG = resibufogenin, RAS = renin–angiotensin system, AT1-AA = agonistic autoantibodies to the AT1 receptor, MAPK = mitogen-
activated protein kinase, IL-6 = interleukin 6, BP = blood pressure, IUGR = intrauterine growth restriction. *The pathogenetic mechanisms occur at an earlier time than the
appearance of the phenotypic features.
1251J.B. Puschett et al. / Biochimica et Biophysica Acta 1802 (2010) 1246–1253example, of p38 or cytokines such as IL-6. These entities appear to be
involved in the ﬁnal pathway by which excessive MBG produces its
noxious effects. In Fig. 6 are provided concepts of a three-phase
process by which preeclampsia occurs. It will be noted that many of
the proposed events have been demonstrated thus far only in the
animal model. However, based upon the evidence emanating from
many laboratories and clinics, it would appear that potentially
exciting observations will result, allowing for the control of
preeclampsia, a disease process with often devastating consequences.
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